Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-inflammation Treatment Combined With Tofacitinib and Doxycycline in Rosacea
NCT07343635Recruiting
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Feb 2026
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Single-blind trial of tofacitinib oral solution and mucopolysaccharide polysulphate in rosacea (3 arms), sponsored by The Fourth Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Investigator's Global Assessment Treatment Success at 12 weeks. Started Feb 2026; status: recruiting.
02
Drugs
tofacitinib oral solutionmucopolysaccharide polysulphate
03
Conditions
rosacea
Beyond the preview
Go deeper on NCT07343635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07343635.